Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEMBRAINS trial in melanoma brain metastases requiring steroids
2024-516585-11-00Phase 2Completed
- Sponsor
- Capital Region of Denmark
- Start
- Jun 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab, ipilimumab, nivolumab, dabrafenib + trametinib, trametinib and 2 more in melanoma (3 arms), sponsored by Capital Region of Denmark. Primary endpoints: 6-month progression-free survival rate and 6-month overall survival rate. Started Jun 2018; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on 2024-516585-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516585-11-00.